Tesofensine/Metoprolol

DRUG3 trials

Sponsors

Saniona

Conditions

Confirmed Genetic Diagnosis of Prader-Willi SyndromeHypothalamic Injury-induced Obesity (HIO)Type 2 Diabetes Mellitus

Phase 2

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

CompletedNCT02737891

SanionaType 2 Diabetes Mellitus

Start: 2016-04-30End: 2017-03-31Updated: 2020-05-14

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

CompletedNCT03149445

SanionaConfirmed Genetic Diagnosis of Prader-Willi Syndrome

Start: 2017-03-30End: 2019-07-22Updated: 2024-02-26

48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)

CompletedNCT03845075

SanionaHypothalamic Injury-induced Obesity (HIO)

Start: 2019-02-25End: 2020-10-16Updated: 2024-02-13

Related Papers

ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity

Journal of the Endocrine Society2022-11-01

Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity

Journal of the Endocrine Society2021-05-014 citations